



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

2 December 2021

IBXO Options Exercise Complete

MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to advise that it has now received the full \$4.8 million from the exercise of all 96,706,395 listed options (IBXO) which had an expiry date of 26 November 2021 and were exercisable at \$0.05.

Since the IBXO options listed in November 2019 a total of 94,708,863 options have been exercised by option holders with the balance of 1,997,532 being exercised by the Underwriter, pursuant to the Underwriting Agreement announced on 25 November 2021.

The Company has lodged an Appendix 2A in relation to the exercise of the final balance of IBXO and a cleansing statement pursuant to section 708A(5)(e) of the Corporations Act for the shares issued pursuant to the Underwriting Agreement.

Executive Chairman and CEO Bob Proulx said, “We are grateful for the support from our option holders and pleased to welcome a quality US based institutional investor to the register. Receiving the maximum funds from the IBXO options has strengthened our cash reserves as we continue towards completion of our MagSense® Phase I study and the development of our platform technology.”

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Evonne Grosso, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61 (0) 450603182